keyword
MENU ▼
Read by QxMD icon Read
search

Zoster vaccine

keyword
https://www.readbyqxmd.com/read/28727683/notes-from-the-field-hospital-contact-investigation-for-a-patient-who-developed-a-zoster-vaccine-related-rash-maryland-february-2015
#1
Diana P Le, Jamie Vega, Lucas A Johnson
No abstract text is available yet for this article.
July 21, 2017: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/28725563/atypical-hemolytic-uremic-syndrome-triggered-by-varicella-infection
#2
Pauline Condom, Jean-Michel Mansuy, Stéphane Decramer, Jacques Izopet, Catherine Mengelle
Varicella Zoster Virus (VZV) is a well-known virus that belongs to the Herpesviridae family which induces a self-limited disease except in specific cases in particular among stem cell transplant patients. This virus is not known however to trigger atypical Hemolytic Uremic Syndrome (aHUS). Here we report the case of a six-year-old boy who was hospitalized with fever and abdominal pains associated to pruritic and vesicular rash, thrombocytopenia and acute renal failure. He was diagnosed with aHUS precipitated by varicella virus...
2017: IDCases
https://www.readbyqxmd.com/read/28725322/recurrent-body-rash-warranted-second-desensitization-with-acyclovir-in-a-myeloma-patient-a-case-report
#3
Jack T Seki, Pamela Ng, Wallace Lam, Julie Cote, Anca Prica
A 75-year-old woman developed a moderately severe rash about a week and a half after the start of bortezomib (Btb)-based chemotherapy for IgG lambda multiple myeloma; at the time, she was also receiving acyclovir as antiviral prophylaxis in addition to herpes zoster (HZ) vaccination. HZ reactivation rate is high in Btb recipients; therefore, the timing of antiviral prevention is critical in relation to Btb. Attempts were made to identify the offending agent based on the timing of drugs administered and the appearance of skin lesions in relation to other drugs...
August 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/28711084/herpes-zoster-in-psoriasis-patients-treated-with-tofacitinib
#4
Kevin L Winthrop, Mark Lebwohl, Arnon D Cohen, Jeffrey M Weinberg, Stephen K Tyring, Scott T Rottinghaus, Pankaj Gupta, Kaori Ito, Huaming Tan, Mandeep Kaur, Alexander Egeberg, Lotus Mallbris, Hernan Valdez
BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor. Immunomodulatory therapies can increase the risk for herpes zoster (HZ) in patients with psoriasis. OBJECTIVE: To evaluate the relationship between tofacitinib use and HZ risk. METHODS: We used phases 2 and 3 and long-term extension (LTE) data from the tofacitinib development program in psoriasis to calculate HZ incidence rates (IR; events per 100 patient-years); potential HZ risk factors were evaluated using Cox-proportional hazard models...
August 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28708959/assessment-of-the-potential-public-health-impact-of-herpes-zoster-vaccination-in-germany
#5
Desmond Curran, Desirée Van Oorschot, Lijoy Varghese, Lidia Oostvogels, Tomas Mrkvan, Romulo Colindres, Alfred von Krempelhuber, Anastassia Anastassopoulou
The aim of this study was to compare the public health impact of introducing two Herpes Zoster (HZ) vaccines, Zoster Vaccine Live (ZVL) versus a non-live adjuvanted subunit candidate vaccine (HZ/su), in the German population aged 50+ years split into three age cohorts, i.e. 50-59, 60-69 and 70+ years, respectively. A multi-cohort static Markov model was developed following age cohorts over their lifetime. Demographic data were obtained from the German federal statistical office. HZ incidence and the proportion of HZ individuals developing post-herpetic neuralgia (PHN) were derived from German specific sources...
July 14, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28705150/economic-burden-of-varicella-in-children-1-12%C3%A2-years-of-age-in-hungary-2011-2015
#6
Z Meszner, Z Molnar, E Rampakakis, H K Yang, B J Kuter, Lara J Wolfson
BACKGROUND: Although live-attenuated varicella-zoster virus (VZV) vaccines have been proven to be safe and effective in preventing varicella and real-word evidence shows routine childhood immunization programs are effective in dramatically reducing varicella associated morbidity and mortality, varicella vaccine is not included in the National Immunization Program (NIP) in Hungary. The purpose of this study was to evaluate the clinical and economic burden associated with varicella in Hungary...
July 14, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28684648/a-cross-sectional-study-of-the-knowledge-attitude-and-practice-of-patients-aged-50-years-or-above-towards-herpes-zoster-in-an-out-patient-setting
#7
A Cy Lam, M Y Chan, H Y Chou, S Y Ho, H L Li, C Y Lo, K F Shek, S Y To, K K Yam, I Yeung
INTRODUCTION: There has been limited research on the knowledge of and attitudes about herpes zoster in the Hong Kong population. This study aimed to investigate the knowledge, attitude, and practice of patients aged 50 years or above towards herpes zoster and its vaccination. METHODS: This was a cross-sectional study in the format of a structured questionnaire interview carried out in Sai Ying Pun Jockey Club General Outpatient Clinic in Hong Kong. Knowledge of herpes zoster and its vaccination was assessed, and patient attitudes to and concerns about the disease were evaluated...
July 7, 2017: Hong Kong Medical Journal, Xianggang Yi Xue za Zhi
https://www.readbyqxmd.com/read/28668813/the-herpes-zoster-vaccine-in-rheumatic-diseases-duration-of-response
#8
EDITORIAL
Erin Shirley, Eliza F Chakravarty
No abstract text is available yet for this article.
July 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28657969/varicella-related-primary-healthcare-visits-hospitalizations-and-mortality-in-norway-2008-2014
#9
Grazina Mirinaviciute, Erle Kristensen, Britt Nakstad, Elmira Flem
BACKGROUND: Norway does not currently implement universal varicella vaccination in childhood. We aimed to characterize healthcare burden of varicella in Norway in the pre-vaccine era. METHODS: We linked individual patient data from different national registries to examine varicella vaccinations and varicella-coded primary care consultations, hospitalizations, outpatient hospital visits, deaths, and viral infections of central nervous system (CNS) in the whole population of Norway during 2008-2014...
June 27, 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28646959/is-chickenpox-so-bad-what-do-we-know-about-immunity-to-varicella-zoster-virus-and-what-does-it-tell-us-about-the-future
#10
Anne A Gershon
Varicella and zoster continue to cause significant morbidity and even mortality in children and adults. Complications include bacterial superinfection, central nervous system manifestations such as meningitis, encephalitis, and cerebellar ataxia, and pain syndromes especially post herpetic neuralgia. Many developed countries but not all, are now administering live attenuated varicella vaccine routinely, with a decrease in the incidence of disease, providing personal and herd immunity. There is some controversy, however, in some countries concerning whether a decrease in the circulation of wild type virus will result in loss of immunity to VZV in persons who have already had varicella...
June 2017: Journal of Infection
https://www.readbyqxmd.com/read/28644696/varicella-vaccination-the-global-experience
#11
Peter Wutzler, Paolo Bonanni, Margaret Burgess, Anne Gershon, Marco Aurélio Sáfadi, Giacomo Casabona
Introduction Varicella, although a frequently benign childhood disease, nevertheless represents a considerable health burden. WHO recommends including varicella vaccines in universal routine vaccination programs, and maintaining coverage >80%. Many countries have successfully introduced varicella vaccination and have benefited from lower disease burden, but many others have not adopted the vaccine. Reasons include cost commitment for a 'mild childhood disease' or concerns that vaccination will shift varicella to older age groups or increase herpes zoster incidence...
June 23, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28636704/trends-in-nationwide-herpes-zoster-emergency-department-utilization-from-2006-to-2013
#12
Erica D Dommasch, Cara J Joyce, Arash Mostaghimi
Importance: The effect of vaccination on emergency department (ED) utilization for herpes zoster (HZ) has not been examined to date. Objective: To determine trends in US ED utilization and costs associated with HZ. Design, Setting, and Participants: The Nationwide Emergency Department Sample data set was examined for temporal trends in the number of visits and costs for treatment of HZ in EDs in the United States from January 1, 2006, through December 31, 2013...
June 21, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28633742/cutaneous-varicella-zoster-virus-infection-following-zoster-vaccination-report-of-post-vaccination-herpes-zoster-skin-infection-and-literature-review-of-zoster-vaccination-efficacy-and-guidelines
#13
Katherine M Stiff, Philip R Cohen
BackgroundHerpes zoster vaccine is currently recommended in the United States for immune competent individuals ≥60 years. The efficacy of the herpes zoster vaccine decreases with age and with time following vaccination.PurposeAn elderly man with herpes zoster following vaccination is described. The guidelines for vaccination and issues regarding re-vaccination are reviewed. METHODS: PubMed was used to search the following terms: efficacy, elderly, herpes zoster, herpes zoster incidence, herpes zoster recurrence, and vaccination...
June 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28629665/efficacy-and-safety-of-tofacitinib-monotherapy-tofacitinib-with-methotrexate-and-adalimumab-with-methotrexate-in-patients-with-rheumatoid-arthritis-oral-strategy-a-phase-3b-4-double-blind-head-to-head-randomised-controlled-trial
#14
Roy Fleischmann, Eduardo Mysler, Stephen Hall, Alan J Kivitz, Robert J Moots, Zhen Luo, Ryan DeMasi, Koshika Soma, Richard Zhang, Liza Takiya, Svitlana Tatulych, Christopher Mojcik, Sriram Krishnaswami, Sujatha Menon, Josef S Smolen
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative efficacy of tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequate response to methotrexate. METHODS: ORAL Strategy was a 1 year, double-blind, phase 3b/4, head-to-head, non-inferiority, randomised controlled trial in patients aged 18 years or older with active rheumatoid arthritis despite methotrexate therapy...
June 15, 2017: Lancet
https://www.readbyqxmd.com/read/28613146/revisiting-the-genotyping-scheme-for-varicella-zoster-viruses-based-on-whole-genome-comparisons
#15
Nancy J Jensen, Pierre Rivailler, Hung Fu Tseng, Mark L Quinlivan, Kay Radford, Jennifer Folster, Rafael Harpaz, Philip LaRussa, Steven Jacobsen, D Scott Schmid
We report whole-genome sequences (WGSs) for four varicella-zoster virus (VZV) samples from a shingles study conducted by Kaiser Permanente of Southern California. Comparative genomics and phylogenetic analysis of all published VZV WGSs revealed that strain KY037798 is in clade IX, which shall henceforth be designated clade 9. Previously published single nucleotide polymorphisms (SNP)-based genotyping schemes fail to discriminate between clades 6 and VIII and employ positions that are not clade-specific. We provide an updated list of clade-specific positions that supersedes the list determined at the 2008 VZV nomenclature meeting...
June 2017: Journal of General Virology
https://www.readbyqxmd.com/read/28608255/temporal-trends-in-herpes-zoster-related-hospitalizations-in-italy-2001-2013-differences-between-regions-that-have-or-have-not-implemented-varicella-vaccination
#16
Nicoletta Valente, Silvia Cocchio, Armando Stefanati, Tatjana Baldovin, Domenico Martinelli, Rosa Prato, Vincenzo Baldo, Giovanni Gabutti
BACKGROUND: Herpes zoster (HZ) has a relevant impact on the population in terms of incidence and complications. AIMS: The aim of this study was to estimate the HZ-related hospitalization rates in Italy in the period 2001-2013, and to evaluate the trend of hospitalizations in the course of time pointing out any differences between regions that have or have not introduced universal childhood varicella immunization (UVI). METHODS: A retrospective analysis was conducted on hospital discharge records contained in the national database of the Ministry of Health for the period January 2001-December 2013...
June 12, 2017: Aging Clinical and Experimental Research
https://www.readbyqxmd.com/read/28607114/varicella-zoster-virus-specific-cellular-immune-responses-to-the-live-attenuated-zoster-vaccine-in-young-and-older-adults
#17
Adriana Weinberg, Jennifer Canniff, Nadine Rouphael, Aneesh Mehta, Mark Mulligan, Jennifer A Whitaker, Myron J Levin
The incidence and severity of herpes zoster (HZ) increases with age. The live attenuated zoster vaccine generates immune responses similar to HZ. We compared the immune responses to zoster vaccine in young and older to adults to increase our understanding of the immune characteristics that may contribute to the increased susceptibility to HZ in older adults. Young (25-40 y; n = 25) and older (60-80 y; n = 33) adults had similar magnitude memory responses to varicella-zoster virus (VZV) ex vivo restimulation measured by responder cell-frequency and flow cytometry, but the responses were delayed in older compared with young adults...
July 15, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28605285/analysis-of-real-world-health-care-costs-among-immunocompetent-patients-aged-50%C3%A2-years-or-older-with-herpes-zoster-in-the-united-states
#18
Juliana L Meyers, Shweta Madhwani, Debora Rausch, Sean D Candrilli, Girishanthy Krishnarajah, Songkai Yan
Few peer-reviewed publications present real-world United States (US) data describing resource utilization and costs associated with herpes zoster (HZ) and postherpetic neuralgia (PHN). The primary objective of this analysis (GSK study identifier: HO-14-14270) was to assess direct costs associated with HZ and PHN in the US using a retrospective managed care insurance claims database. Patients ≥ 50 y at HZ diagnosis were selected. Patients were excluded if they were immunocompromised before diagnosis or received an HZ vaccine at any time...
June 12, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28592229/the-intention-of-dutch-general-practitioners-to-offer-vaccination-against-pneumococcal-disease-herpes-zoster-and-pertussis-to-people-aged-60%C3%A2-years-and-older
#19
Birthe A Lehmann, Renske Eilers, Liesbeth Mollema, José Ferreira, Hester E de Melker
BACKGROUND: Increasing life expectancy results in a larger proportion of older people susceptible to vaccine preventable diseases (VPDs). In the Netherlands, influenza vaccination is routinely offered to people aged 60 years and older. Vaccination against pneumococcal disease, herpes zoster and pertussis is rarely used. These vaccines will be evaluated by the Dutch Health Council and might be routinely offered to older people in the near future. Possible expansion of the program depends partly on the willingness of general practitioners (GPs) to endorse additional vaccinations...
June 7, 2017: BMC Geriatrics
https://www.readbyqxmd.com/read/28582374/management-of-corneal-scarring-secondary-to-herpes-zoster-keratitis
#20
Omar M Hassan, Asim V Farooq, Ketki Soin, Ali R Djalilian, Joshua H Hou
PURPOSE: To review the management of visually significant corneal scarring secondary to herpes zoster keratitis (HZK). METHODS: Literature review. RESULTS: Management options for visually significant corneal scarring secondary to HZK include scleral contact lenses, photorefractive or phototherapeutic keratectomy, lamellar keratoplasty, penetrating keratoplasty, and keratoprosthesis. Many authors recommend tarsorrhaphy in at-risk patients at the time of corneal transplantation...
June 2, 2017: Cornea
keyword
keyword
32230
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"